New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Mezzaroba, Nelly ^a   Zorzet, Sonia ^a   Secco, Erika ^a   Biffi, Stefania ^b   Tripodo, Claudio ^c   Calvaruso, Marco ^c   Mendoza Maldonado, Ramiro ^d   Capolla, Sara ^a   Granzotto, Marilena ^b   Spretz, Ruben ^e   Larsen, Gustavo ^e,f   Noriega, Sandra ^e   Lucafò, Marianna ^a   Mansilla, Eduardo ^g   Garrovo, Chiara ^h   Marín, Gustavo H ^g   Baj, Gabriele ^a   Gattei, Valter ⁱ   Pozzato, Gabriele ^a   Núñez, Luis ^f,j   Macor, Paolo ^a   more..

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^e LNKChemsolutions   (United States)

^f Bio Target   (United States)

^g Ministerio de Salud de la provincia de Buenos Aires   (Argentina)

^h Optical Imaging Laboratory   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CHLORAMBUCIL; HYDROXYCHLOROQUINE; NANOPARTICLE; PROTEIN P53; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CONTROL; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DRUG COATING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; FEMALE; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; APOPTOSIS; AUTOPHAGY; CELL SURVIVAL; CHLORAMBUCIL; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; FLOW CYTOMETRY; HYDROXYCHLOROQUINE; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MICE; MICE, SCID; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES;

EID: 84884741190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074216     Document Type: Article

References (55)

1. IARC (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue; S. Swerdlow EC, N. Lee Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, editor. Lyon.
2. de Jong D, Balague Ponz O, (2011) The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. J Pathol 223: 274-282.
3. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, et al. (2011) CD38 and chronic lymphocytic leukemia: a decade later. Blood 118: 3470-3478.
4. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, et al. (2012) Burkitt's lymphoma. Lancet 379: 1234-1244.
5. Cheson BD, (2006) Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 55: 188-196.
6. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12: 1763-1769; discussion 1769-1770, 1775-1767.
7. Fayad L, Thomas D, Romaguera J, (2007) Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 8Suppl 2: S57-62.
8. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, et al. (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112: 2248-2260.
9. Bloehdorn J, Langer C, Döhner H, Zenz T, Stilgenbauer S, (2010) P53 and microRNAs in chronic lymphocytic leukemia. Journal of Nucleic Acids Investigation volume 2: e8.
10. Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, et al. (2009) Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 113: 3773-3780.
11. Bae KH, Chung HJ, Park TG, (2011) Nanomaterials for cancer therapy and imaging. Mol Cells 31: 295-302.
12. Davis ME, Chen ZG, Shin DM, (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
13. Duncan R, (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347-360.
14. Vasir JK, Labhasetwar V, (2007) Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 59: 718-728.
15. Chiellini F, Piras AM, Errico C, Chiellini E, (2008) Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine (Lond) 3: 367-393.
16. Feng SS, (2006) New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now? Nanomedicine (Lond) 1: 297-309.
17. Feng SS, (2008) Nanoparticles of biodegradable polymers for cancer treatment. Biomaterials 29: 4146-4147.
18. Parveen S, Sahoo SK, (2008) Polymeric nanoparticles for cancer therapy. J Drug Target 16: 108-123.
19. Pridgen EM, Langer R, Farokhzad OC, (2007) Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) 2: 669-680.
20. Ruoslahti E, Bhatia SN, Sailor MJ, (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188: 759-768.
21. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760.
22. Agemy L, Sugahara KN, Kotamraju VR, Gujraty K, Girard OM, et al. (2010) Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116: 2847-2856.
23. Acharya S, Dilnawaz F, Sahoo SK, (2009) Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30: 5737-5750.
24. Bicho A, Peca IN, Roque AC, Cardoso MM, (2010) Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8. Int J Pharm 399: 80-86.
25. Marin GH, Mansilla E, Mezzaroba N, Zorzet S, Nunez L, et al. (2010) Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. Curr Clin Pharmacol 5: 246-250.
26. Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, et al. (2008) In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging 7: 272-282.
27. Zabucchi G, Menegazzi R, Soranzo MR, Patriarca P, (1986) Uptake of human eosinophil peroxidase by human neutrophils. Am J Pathol 124: 510-518.
28. Mendoza-Maldonado R, Paolinelli R, Galbiati L, Giadrossi S, Giacca M, (2010) Interaction of the retinoblastoma protein with Orc1 and its recruitment to human origins of DNA replication. PLoS One 5: e13720.
29. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, et al. (2007) In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67: 10556-10563.
30. Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, et al. (2010) ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 120: 1262-1273.
31. Xie Z, Klionsky DJ, (2007) Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9: 1102-1109.
32. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, et al. (2005) Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 35: 2175-2183.
33. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P, (2003) Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 4098-4104.
34. Kalil N, Cheson BD, (2000) Management of chronic lymphocytic leukaemia. Drugs Aging 16: 9-27.
35. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654-666.
36. Mansilla E, Marin GH, Nunez L, Drago H, Sturla F, et al. (2010) The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro. Cancer Biother Radiopharm 25: 97-103.
37. Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, et al. (2002) Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma 43: 1087-1095.
38. Rahim R, Strobl JS, (2009) Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20: 736-745.
39. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, et al. (2011) Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 17: 762-770.
40. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, et al. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900-3908.
41. Krystof V, Uldrijan S, (2010) Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 11: 291-302.
42. Stein M, Bell MJ, Ang LC, (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27: 2927-2931.
43. Tehrani R, Ostrowski RA, Hariman R, Jay WM, (2008) Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 23: 201-209.
44. Rao DA, Forrest ML, Alani AW, Kwon GS, Robinson JR, (2010) Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 99: 2018-2031.
45. Verma A, Uzun O, Hu Y, Han HS, Watson N, et al. (2008) Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater 7: 588-595.
46. Mayor S, Pagano RE, (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8: 603-612.
47. Rima W, Sancey L, Aloy MT, Armandy E, Alcantara GB, et al. (2013) Internalization pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles. Biomaterials 34: 181-195.
48. Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, et al. (2011) Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res 71: 7481-7489.
49. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
50. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, et al. (2006) The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91: 176-183.
51. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, et al. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171: 1581-1587.
52. Macor P, Tedesco F, (2007) Complement as effector system in cancer immunotherapy. Immunol Lett 111: 6-13.
53. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, et al. (2003) Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88: 1002-1012.
54. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, et al. (2001) Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98: 2771-2777.
55. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, et al. (2008) Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park) 22: 1508-1517.